Form 4: Director Amrit Ray Receives Ultragenyx Equity Grant
Statement of Changes in Beneficial Ownership
Director Amrit Ray was granted 7,751 restricted stock units and 14,058 stock options as part of the Ultragenyx 2023 Incentive Plan.
Summary
- Director Amrit Ray acquired 7,751 Restricted Stock Units (RSUs) on May 14, 2026.
- Director Amrit Ray was granted 14,058 stock options with an exercise price of $25.80.
- The total beneficial ownership for the director following these transactions is 31,116 shares of common stock.
- Both the RSUs and the stock options are scheduled to vest on the earlier of the next Annual Meeting of Stockholders or May 14, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Standardized incentive structure under the company's 2023 Incentive Plan.
Negatives
- Dilutive impact of new equity grants on existing shareholders.
Risks
- Potential for future share price volatility affecting the value of the granted options.
- Market risk associated with the biotechnology sector.
Future Outlook
The equity grants are subject to vesting conditions tied to the next Annual Meeting of Stockholders or May 14, 2027.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology industry to ensure long-term alignment with corporate performance and shareholder value.
Comparison to Industry Standards
- The use of RSU and option grants is consistent with compensation practices at peer-group mid-cap biotechnology firms.
- Vesting schedules of approximately one year for director equity are common in the industry.
Stakeholder Impact
- Shareholders may experience minor dilution from the issuance of new equity.
Next Steps
- Vesting of equity grants on the earlier of the next Annual Meeting of Stockholders or May 14, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/14/2026 | Transaction date for RSU and stock option grants. |
| 05/14/2027 | Vesting date for RSUs and stock options. |
| 05/14/2036 | Expiration date for the granted stock options. |
Keywords
Ultragenyx, RARE, Form 4, Insider Trading, Equity Compensation, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.